Table VI.

Univariate and multivariate analyses for prognostic factors (intrahepatic recurrence) in group B.

	Univariate analysis	Multivariate analysis
Factors	P	P	HR (95% CI)
pT2 vs. pT3–4	0.809	0.991	12.03 (0.011–62.074)
pN0 vs. pN1–2	0.337	0.728	9.84 (0.339–73.279)
LVI (+ vs. −)	0.043	0.278	5.20 (0.641–28.311)
Disease-free interval (<1 yr vs. >1 yr)	0.038	0.055	8.06 (0.403–37.461)
Postop. CTx. (oxaliplatin vs. irinotecan)	0.847	0.895	33.92 (0.123–100.419)
Use of biological agents (yes vs. no)	0.764	0.925	40.34 (0.250–193.004)
CEA (PV)	0.711	0.886	35.61 (0.213–119.407)
CEA (DV)	0.099	0.280	17.32 (0.801–47.822)
E-selectin (PV)	0.069	0.374	9.07 (0.724–36.770)
E-selectin (DV)	0.040	0.195	9.72 (0.857–40.226)
VEGF (PV)	0.055	0.252	16.09 (0.472–52.238)
VEGF (DV)	<0.001	<0.001	12.16 (1.431–58.348)
TIMP-1 (PV)	0.009	0.042	8.12 (1.983–60.924)
TIMP-1 (DV)	<0.001	0.026	7.40 (1.020–28.653)

CEA, carcinoembryonic antigen; VEGF, vascular endothelial growth factor; TIMP-1, tissue inhibitor of metalloproteinase-1; LVI, lymphovascular invasion; PV, the serum level of a molecule from the peripheral blood; DV, the serum level of a molecule from the drainage vein; CI, confidence interval.